Despite the inevitable resistance upon the administration of the majority of commercial protein kinase inhibitors, they are considered to be promising weapons for prolonging overall survival of cancer patients, owing to their remarkable potency against targeting kinase receptors and the downstream signaling [41,42]. This evidence concerns the gene WEE1 and cancer.